Thursday, July 21st, 2022 at 1 pm ET, Lumira Ventures Principal, Nikhil Thatte hosts the Investor Reverse Pitch Presentation at the 2022 Life Science Future – Medtech Conference. Life Sciences Future – MedTech is an annual event focused on joining …
Trending at Lumira Ventures
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
Positive Phase 1 results reported at the American Association for Thoracic Surgery (AATS) and the American Society of Gene and Cell Therapy (ASGCT) revealed XC001 is well tolerated at all dose levels Phase I data support XC001 therapeutic effect and …
Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)
Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March 31, 2022. All dollar amounts in this press release are in United States …
Lumira Ventures Builds Upon Presence in Western Canada with Partner Lu Han, Ph.D. Expanding Firm’s Vancouver Office
TORONTO, Ontario, June 14, 2022 — Lumira Ventures, a global healthcare venture capital firm, announced today that Partner Lu Han Ph.D. has relocated to the firm’s office in Vancouver, British Colombia. Dr. Han will expand upon Lumira Ventures’ success in …
Corvia Medical Closed $54 Million Financing to Support Planned Confirmatory Trial of the Corvia® Atrial Shunt
Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, Mass., June 9, 2022 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing …
Lumira Ventures Announces Appointment of David Novak as Venture Partner
Accomplished Biotechnology Industry Equity Analyst Will Support Firm’s Public Market Investment Initiatives TORONTO, Ontario, June 7, 2022 — Lumira Ventures, a global healthcare venture capital firm, announced today the addition of David Novak to its investment team as a Venture …
G1 Therapeutics Presents Promising Trilaciclib Data at ASCO
Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy Patients Receiving Trilaciclib Experienced a Lower Incidence of Single-Lineage and Multilineage Chemotherapy-Induced …
HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies
Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy HistoSonics, the developer and manufacturer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the fulfillment of patient enrollment required for …
Lumira Ventures is Looking for a Controller to Join Our Team
Lumira Ventures is an impactful investor and you will share our passion for innovation and being part of a team-building transformative companies. We are a venture capital organization investing capital on behalf of our investors to build best and/or first-in-class …
Nikhil Thatte Hosts Invest Canada 2022: Investing in Life Sciences From Health Tech to Therapeutics Panel Discussion
This Thursday, May 26th, 2022, join Lumira Ventures Principal, Nikhil Thatte as he leads the Investing in Life Sciences from Health Tech to Therapeutics: Driving Impact and Producing Sizable Returns panel discussion. Nikhil along with four other leading US and …
HistoSonics Announces Agreement with GE Healthcare
MINNEAPOLIS, May 23, 2022 — HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare’s LOGIQ E10 Series ultrasound imaging platform to power the real time visualization features of …
XyloCor Therapeutics Presents Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina
Data from the Phase 1 dose-escalation portion of the Phase 1/2 EXACT study demonstrate XC001 was well-tolerated at all dose levels tested; highest dose level evaluated selected for ongoing Phase 2 portion of the study Preliminary efficacy data highlight XC001 …
Alice Luo Presents Lumira Ventures at the 2022 Life Sciences Career Expo
On Wednesday, May 11th, 2022, Lumira Ventures Analyst, Alice Luo will represent Lumira during her company spotlight presentation for the Life Sciences Career Expo: Starting Your Career Journey. The event is a national, multi-day conference designed to bring students and …
Suman Rao Serves as a Business Mentor For The McGill Invention to Impact Training Program
Beginning May 2, 2022 until July 13, 2022, Lumira Ventures Associate, Suman Rao will act as a business mentor to one of the participating teams at the McGill Engine’s Invention to Impact program. Through the duration of the program, Suman …
Nikhil Thatte Speaks at the Open for Business Ontario: Life Sciences Innovation Series
Wednesday, April 6th, 2022, Lumira Ventures Principal, Nikhil Thatte speaks on a panel of industry leaders at the Open for Business Ontario: Life Sciences Innovation Series webinar. During the event, Nikhil provides insight into the industry from a venture capital …